Schonfeld Strategic Advisors LLC Fulcrum Therapeutics, Inc. Transaction History

Schonfeld Strategic Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$6.7 - $12.0 $2.7 Million - $4.84 Million	-403,364 Reduced 93.26%	29,169 $275,000
Q4 2023 Feb 14, 2024	BUY	$3.18 - $6.86 $1.38 Million - $2.97 Million	432,533 New	432,533 $2.92 Million
Q4 2022 Feb 14, 2023	BUY	$5.01 - $8.35 $200,400 - $334,000	40,000 Added 60.06%	106,600 $776,000
Q3 2022 Nov 14, 2022	BUY	$4.92 - $9.1 $177,120 - $327,600	36,000 Added 117.65%	66,600 $539,000
Q2 2022 Aug 15, 2022	SELL	$4.2 - $24.0 $37,800 - $216,000	-9,000 Reduced 22.73%	30,600 $150,000
Q1 2022 May 16, 2022	BUY	$9.96 - $23.65 $40,836 - $96,965	4,100 Added 11.55%	39,600 $936,000
Q4 2021 Feb 14, 2022	SELL	$14.0 - $28.44 $652,400 - $1.33 Million	-46,600 Reduced 56.76%	35,500 $628,000
Q3 2021 Nov 16, 2021	BUY	$7.28 - $30.97 $597,688 - $2.54 Million	82,100 New	82,100 $2.32 Million

150

52.2M

6.91M

1.9M

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $156M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.